Belgium· BE-AMP-SAM596373-00
Saphnelo 300 mg
A anifrolumab product containing anifrolumab, registered in Belgium by AstraZeneca. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Anifrolumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG11 (anifrolumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Anifrolumab · ATC L04AG11
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of anifrolumab costs, country by country.
Normalised to the WHO defined daily dose (10.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Anifrolumab · price per daily dose (10.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$42.60
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Anifrolumab
- Manufacturer
- AstraZeneca
- Country
- Belgium (BE)
- ATC code
- L04AG11
- ATC class
- Anifrolumab
- Defined daily dose
- 10.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4508776
- be_apb7738420
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Anifrolumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSAPHNELOAstraZeneca AB, Södertälje
- FinlandSaphneloAstraZeneca AB
- IrelandSaphnelo 300 mg Concentrate for solution for infusionAstraZeneca AB
- IcelandSaphneloAstraZeneca AB*
- NorwaySaphneloAstraZeneca AB (2)
- PolandSaphneloAstraZeneca AB
- SwedenSAPHNELO 300 mg Koncentrat till infusionsvätska, lösningAstraZeneca AB
- SwitzerlandSaphnelo 120 mg/0.8 ml, Injektionslösung in einem FertigpenAstraZeneca AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Saphnelo
- Liechtenstein · Saphnelo
- Norway · Saphnelo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8f3f9185-7bfd-41ff-aea4-c40063985b2e GET /v1/drugs/8f3f9185-7bfd-41ff-aea4-c40063985b2e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Saphnelo 300 mg",
"name_fr": "Saphnelo 300 mg",
"name_nl": "Saphnelo 300 mg",
"amp_code": "SAM596373-00",
"strengths": [
"150.0000"
],
"pack_count": 1,
"substances": [
"Anifrolumab",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Anifrolumab",
"authorisation_numbers": [
"EU/1/21/1623/001"
]
}See everything about anifrolumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.